SELLAS Life Sciences Group (SLS) Price & Analysis

Compare

1,093 Followers

SLS Stock Chart & Stats

$2.05

-$0.10(-9.43%)

At close: Jan 08 4:00 PM EST

$2.05

-$0.10(-9.43%)

Day’s Range― - ―

52-Week Range$0.77 - $2.27

Previous CloseN/A

Volume1.43M

Average Volume (3M)2.23M

Market Cap

$201.12M

Enterprise Value$191.18M

Total Cash (Recent Filing)$25.40M

Total Debt (Recent Filing)$737.00K

Price to Earnings (P/E)―

Beta1.09

Next Earnings

Nov 12, 2025

EPS Estimate

-0.08

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.07

Shares Outstanding105,297,470

10 Day Avg. Volume2,538,863

30 Day Avg. Volume2,230,586

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.95

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-5.26

Forecast

1Y Price Target

$7.00

Price Target Upside241.46% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical TrialsSellas announced a positive interim analysis from the P3 REGAL study evaluating GPS, its WT1-targeting cancer immunotherapy, in the AML CR2 setting, with a recommendation to continue without modification.

Regulatory ProgressSellas has FDA guidance to move the triplet now to 1L AML, which represents a significant positive for Sellas as it progresses this program.

Stock PerformanceSLS shares continue to rise in value in 2025, up ~90% YTD as the company continues to execute across its acute myeloid leukemia (AML) programs.

Bears Say

Market CompetitionThe company's focus on advancing to a randomized trial targeting first-line AML patients could face challenges due to competition in sub-populations with significant unmet need.

Regulatory ChallengesDespite FDA guidance, advancing the SLS009 triplet into the front-line setting may encounter unforeseen regulatory hurdles that could delay progress.

SELLAS Life Sciences Group News

Sellas Life Sciences to present in vivo preclinical data on SLS009

SELLAS Life Sciences (SLS) announced that preclinical efficacy of its highly selective CDK9 inhibitor, SLS009, as a monotherapy...

2d ago

SLS

Sellas Life Sciences files to sell 19.69M shares of common stock for holders

16:09 EDT Sellas Life Sciences (SLS) files to sell 19.69M shares of common stock for holders Published first...

5d ago

SLS

SELLAS Extends Times Square Sublease Agreement

The latest update is out from SELLAS Life Sciences Group ( ($SLS) ). On October 1, 2025, SELLAS...

12d ago

SLS

SELLAS Life Sciences’ Recent Warrant Inducement Agreement

The latest update is out from SELLAS Life Sciences Group ( ($SLS) ). On September 10, 2025, SELLAS...

1M ago

SLS

Sellas Life Sciences announces exercise of warrants for $23.6M in proceeds

SELLAS Life Sciences (SLS) announced the immediate exercise of warrants, previously issued in January 2025, to purchase up...

1M ago

SLS

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Sealsq Corp (LAES) 30.26%...

1M ago

CEP

MPW

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Lucid Group (LCID) 86.02%...

1M ago

ACB

BHP

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Valkyrie Bitcoin Miners ETF...

2M ago

ACB

BAM

Unusually active option classes on open August 21st

Unusual total active option classes on open include: Dayforce Inc (DAY), Crexendo Inc (EXE), Wal-Mart (WMT), iShares MSCI...

2M ago

ABT

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Gorilla Technology Group Inc...

2M ago

SLS

VOR

Optimistic Buy Rating for SELLAS Life Sciences Group Driven by Promising Trial Results and Financial Stability

SELLAS Life Sciences Group, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason...

2M ago

SLS

Sellas Life Sciences Reports Q2 2025 Financial Results

Sellas Life Sciences Group ( ($SLS) ) has released its Q2 earnings. Here is a breakdown of the...

2M ago

SLS

Sellas Life Sciences reports Q2 EPS (7c), consensus (8c)

“We continue to make significant progress in advancing our AML-focused pipeline, as demonstrated by the positive Phase 2...

2M ago

SLS

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Sequans (SQNS) 85.88% +1.67,...

2M ago

FAZ

SLS FAQ

What was SELLAS Life Sciences Group’s price range in the past 12 months?

SELLAS Life Sciences Group lowest stock price was $0.77 and its highest was $2.27 in the past 12 months.

What is SELLAS Life Sciences Group’s market cap?

SELLAS Life Sciences Group’s market cap is $201.12M.

When is SELLAS Life Sciences Group’s upcoming earnings report date?

SELLAS Life Sciences Group’s upcoming earnings report date is Nov 12, 2025 which is in 28 days.

How were SELLAS Life Sciences Group’s earnings last quarter?

SELLAS Life Sciences Group released its earnings results on Aug 12, 2025. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.077 by $0.007.

Is SELLAS Life Sciences Group overvalued?

According to Wall Street analysts SELLAS Life Sciences Group’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does SELLAS Life Sciences Group pay dividends?

SELLAS Life Sciences Group does not currently pay dividends.

What is SELLAS Life Sciences Group’s EPS estimate?

SELLAS Life Sciences Group’s EPS estimate is -0.08.

How many shares outstanding does SELLAS Life Sciences Group have?

SELLAS Life Sciences Group has 105,297,470 shares outstanding.

What happened to SELLAS Life Sciences Group’s price movement after its last earnings report?

SELLAS Life Sciences Group reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.077. Following the earnings report the stock price went down -3.727%.

Which hedge fund is a major shareholder of SELLAS Life Sciences Group?

Among the largest hedge funds holding SELLAS Life Sciences Group’s share is Highbridge Capital Management LLC. It holds SELLAS Life Sciences Group’s shares valued at 0.

SELLAS Life Sciences Group Stock Smart Score

Neutral

Fundamentals

Return on Equity

-180.71%

Trailing 12-Months

Asset Growth

113.67%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

SELLAS Life Sciences Group

SELLAS Life Sciences Group (SLS) is a biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of cancer indications. The company's core product is galinpepimut-S (GPS), which is designed to stimulate an immune response against specific cancer cells. SELLAS is involved in clinical trials and research collaborations to advance its pipeline and bring innovative cancer treatments to market.

SELLAS Life Sciences Group (SLS) Earnings & Revenues

Historic Earnings Reports

SLS Stock 12 Month Forecast

Average Price Target

$7.00

▲(241.46% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","2":"$2","4":"$4","6":"$6","8":"$8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2,4,6,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.66,2.0707692307692307,2.4815384615384612,2.8923076923076922,3.3030769230769232,3.713846153846154,4.124615384615384,4.535384615384616,4.946153846153846,5.356923076923077,5.7676923076923075,6.178461538461539,6.5892307692307694,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.66,2.0707692307692307,2.4815384615384612,2.8923076923076922,3.3030769230769232,3.713846153846154,4.124615384615384,4.535384615384616,4.946153846153846,5.356923076923077,5.7676923076923075,6.178461538461539,6.5892307692307694,{"y":7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.66,2.0707692307692307,2.4815384615384612,2.8923076923076922,3.3030769230769232,3.713846153846154,4.124615384615384,4.535384615384616,4.946153846153846,5.356923076923077,5.7676923076923075,6.178461538461539,6.5892307692307694,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.28,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.04,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.58,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >